来自MSN1 个月
Pfizer’s colon cancer combo approval further supported by Phase III win
The active control group received mFOLFOX6, FOLFOXIRI (Folinic acid, fluorouracil, oxaliplatin and irinotecan), or CAPOX (capecitabine and oxaliplatin) with or without bevacizumab. A BRAF mutation ...